Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.20USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$3.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
684,276
52-wk High
$4.71
52-wk Low
$2.15

Select another date:

Tue, May 1 2018

BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17

* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Rigel Pharmaceuticals Says Expects To Report About $94.3 Mln Cash, Cash Equivalents, Short-Term Investments As Of March 31, 2018

* RIGEL PHARMACEUTICALS SAYS EXPECTS TO REPORT IT HAD ABOUT $94.3 MILLION CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 - SEC FILING Source text: (https://bit.ly/2Jedbsn) Further company coverage:

BRIEF-Rigel Announces Pricing Of Public Offering Of Common Stock

* PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC Source text for Eikon: Further company coverage:

BRIEF-Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering

* RIGEL PHARMACEUTICALS INC - INTENDS TO OFFER & SELL UP TO 15 MILLION SHARES OF ITS STOCK IN AN UNDERWRITTEN PUBLIC OFFERING

BRIEF-Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA

* RIGEL PHARMACEUTICALS NDA FOR TAVALISSE APPROVED BY FDA Source text: (http://bit.ly/2HGn96a) Further company coverage:

FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder

The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder.

FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder

April 17 The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder.

BRIEF-Rigel Makes Statement Regarding Website Error

* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17

REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib

* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY

BRIEF-Rigel Pharma Files For Mixed Shelf Of Up To $200 Mln

* RIGEL PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​ Source text (http://bit.ly/2FoyDNx) Further company coverage:

Select another date: